Report: Current Stock Reports

Changes in Ryvu’s Management Board
July 26, 2022

Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
July 8, 2022

Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
July 7, 2022

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
July 1, 2022

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
July 1, 2022

Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
June 10, 2022

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
June 3, 2022

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
May 12, 2022

Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
April 27, 2022

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
April 1, 2022